Actuate Therapeutics Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACTU research report →
About the company
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma.
- CEO
- Daniel Schmitt
- IPO
- 2024
- Employees
- 10
- HQ
- Fort Worth, TX, US
Price Chart
- Market Cap
- $36.37M
- P/E
- -1.54
- P/S
- 0.00
- P/B
- 9.45
- EV/EBITDA
- -1.33
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -430.93%
- ROIC
- -521.19%
- Revenue
- $0 · 0.00%
- Net Income
- $-22,227,852 · 18.54%
- EPS
- $-1.06 · 67.48%
- Op Income
- $-22,495,312
- FCF YoY
- 12.07%
- 52W High
- $9.22
- 52W Low
- $1.40
- 50D MA
- $2.33
- 200D MA
- $4.57
- Beta
- 0.68
- Avg Volume
- 183.27K
Get TickerSpark's AI analysis on ACTU
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 21, 26 | Zabrowski Dan | other | 15,000 |
| May 21, 26 | THOMSON TODD S | other | 15,000 |
| May 21, 26 | Sawhney Roger | other | 15,000 |
| May 21, 26 | RONNEBERG AMY L | other | 15,000 |
| May 21, 26 | Keyes Jason A | other | 15,000 |
| May 21, 26 | Huber Martin H. Jr. | other | 15,000 |
| May 21, 26 | Fletcher Aaron G.L. | other | 15,000 |
| May 1, 26 | Huber Martin H. Jr. | other | 30,000 |
| Apr 1, 26 | SCHMITT DANIEL M | other | 237,000 |
| Apr 1, 26 | Mazar Andrew Paul | other | 105,000 |
Our ACTU coverage
Recent articles, reports, and earnings notes.
No research on ACTU yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACTU report →Similar companies
Peers in the same neighborhood.